Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. (23rd October 2017)

• Record Type: Journal Article
• Authors: Ghorani, E; Rosenthal, R; McGranahan, N; Reading, J L; Lynch, M; Peggs, K S; Swanton, C; Quezada, S A
• Is Part Of: Annals of oncology. Volume 29:Number 1(2018)
• Page Start: 271
• Page End: 279
• Publication Date: 2017-10-23
• Subjects: peptide immunogenicity -- neoantigen prediction -- immunoinformatics -- immunotherapy; Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdx687
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Background: Cancer mutations generate novel (neo-)peptides recognised by T cells, but the determinants of recognition are not well characterised. The difference in predicted class I major histocompatibility complex (MHC-I) binding affinity between wild-type and corresponding mutant peptides (differential agretopicity index; DAI) may reflect clinically relevant cancer peptide immunogenicity. Our aim was to explore the relationship between DAI, measures of immune infiltration and patient outcomes in advanced cancer. Patients and methods: Cohorts of patients with advanced non-small-cell lung cancer (NSCLC; LUAD, n = 66) and melanoma (SKCM, n = 72) were obtained from The Cancer Genome Atlas. Three additional cohorts of immunotherapy treated patients with advanced melanoma (total n = 131) and NSCLC ( n = 31) were analysed. Neopeptides and their clonal status were defined using genomic data. MHC-I binding affinity was predicted for each neopeptide and DAI values summarised as the sample mean DAI. Correlations between mean DAI and markers of immune activity were evaluated using measures of lymphocyte infiltration and immune gene expression. Results: In univariate and multivariate analyses, mean DAI significantly correlated with overall survival in 3/5 cohorts, with evidence of superiority over nonsynonymous mutational and neoantigen burden. In these cohorts, the effect was seen for mean DAI of clonal but not subclonal peptides. In SKCM, the association between mean DAI and survival bordered significance ( P = 0.068), reaching significance in an immunotherapy-treated melanoma cohort ( P = 0.003). Mean DAI but not mutational nor neoantigen burden was positively correlated with independently derived markers of immune infiltration in both SKCM ( P = 0.027) and LUAD ( P = 0.024). Conclusions: The association between mean DAI, survival and measures of immune activity support the hypothesis that DAI is a determinant of cancer peptide immunogenicity. Investigation of DAI as a marker of immunologically relevant peptides in further datasets and future clinical studies of neoantigen based immunotherapies is warranted.